Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| REGN | PRESS-RELEASE | neutral | 1/10 | Regeneron Pharmaceuticals, Inc. announced it will report its Q3 2026 results on October 30, 2026. | Sep 24, 2026 |
| PRME | PRESS-RELEASE | bullish | 7/10 | Prime Medicine announced FDA clearance of its IND application for PM647, an in vivo Prime Editor for Alpha-1 Antitrypsin | Sep 24, 2026 |
| GMAB | 6-K | neutral | 2/10 | Genmab granted 13,794 restricted stock units and 13,331 warrants to employees as routine equity compensation. The RSUs h | Sep 24, 2026 |
| GSK | 6-K | neutral | 1/10 | GSK filed a routine 6-K disclosing that Maya Martinez-Davis, President US, acquired 9.414 notional ADS at $50.72 within | Sep 24, 2026 |
| PHVS | CLUSTER | bearish | 5/10 | Eight insiders at Pharvaris sold a total of ~$7.35M in open-market sales over a 7-day window, including the President ($ | Sep 24, 2026 |
| PHVS | CLUSTER | bearish | 7/10 | Eight Pharvaris insiders sold a total of $7.35M in open-market sales over a one-week window, including the President ($3 | Sep 24, 2026 |
| JAGX | 424B5 | bearish | 5/10 | Jaguar Health filed Supplement No. 8 to its ATM prospectus, disclosing that it has approximately $9.82 million remaining | Sep 24, 2026 |
| CELU | PRESS-RELEASE | mixed | 6/10 | Celularity announced an initial closing of a private placement of senior secured convertible notes and warrants generati | Sep 24, 2026 |
| BDRX | F-1 | bearish | 5/10 | Biodexa Pharmaceuticals filed an F-1 registration statement to register 220,421,800 ordinary shares (represented by 4,40 | Sep 24, 2026 |
| HCWB | 8-K | bearish | 6/10 | HCW Biologics entered into a securities purchase agreement on September 23, 2026, to sell shares of common stock, pre-fu | Sep 24, 2026 |
| NGEN | 6-K | neutral | 3/10 | NervGen Pharma Corp. filed a Form 6-K announcing the resignation of KPMG Canada as its auditor and the appointment of KP | Sep 24, 2026 |
| CRL | 8-K | bullish | 6/10 | Charles River Laboratories held its 2026 Investor Day, reaffirming full-year 2026 guidance and introducing long-term fin | Sep 24, 2026 |
| APVO | 8-K | neutral | 3/10 | Aptevo Therapeutics announced progress in its next-generation trispecific programs, focusing on scalable manufacturing f | Sep 24, 2026 |
| TANH | 6-K | neutral | 4/10 | Tantech Holdings Ltd announced it regained compliance with Nasdaq's minimum bid price rule (Listing Rule 5550(a)(2)) aft | Sep 24, 2026 |
| QNTM | 6-K | neutral | 3/10 | Quantum Biopharma's licensee Unbuzzd Wellness appointed Michael Zapolin as CEO with a mandate to finance and list Unbuzz | Sep 24, 2026 |
| KALA | PRESS-RELEASE | neutral | 3/10 | Kala Bio announced a non-binding LOI under which a U.S. DNA testing platform would resell Virotek's genomic testing prod | Sep 24, 2026 |
| IMRN | 20-F | mixed | 5/10 | Immuron Ltd filed its annual report on Form 20-F for the fiscal year ended June 30, 2026. Revenue increased 6% to A$7.7M | Sep 24, 2026 |
| CGEM | 8-K | neutral | 5/10 | Cullinan Therapeutics outlined Q4 2026 milestones across its T cell engager pipeline, including multi-dose data for CLN- | Sep 24, 2026 |
| LGND | 8-K | neutral | 3/10 | Ligand Pharmaceuticals entered into a financing agreement with AvenCell Therapeutics for up to $47 million, comprising u | Sep 24, 2026 |
| VTGN | 8-K | neutral | 4/10 | Vistagen reported positive exploratory data for fasedienol nasal spray in very severe social anxiety disorder at Psych C | Sep 24, 2026 |
| MSLE | 6-K | bullish | 7/10 | Satellos announced FDA clearance of its IND application for forazapadin in FSHD, a second indication with no approved th | Sep 24, 2026 |
| VTGN | PRESS-RELEASE | neutral | 4/10 | Vistagen presented positive exploratory data at Psych Congress 2026 showing a potential efficacy signal for fasedienol i | Sep 24, 2026 |
| CGEM | PRESS-RELEASE | bullish | 6/10 | Cullinan Therapeutics announced upcoming Q4 2026 pipeline milestones for its T cell engager programs, including multi-do | Sep 24, 2026 |
| MSLE | PRESS-RELEASE | bullish | 6/10 | Satellos received FDA clearance for its IND application for forazapadin in FSHD, a second degenerative muscle disease wi | Sep 24, 2026 |
| SPRC | 6-K | neutral | 3/10 | SciSparc subsidiary NeuroThera announced the publication of three U.S. patent applications covering combinations of its | Sep 24, 2026 |
| HCM | 6-K | bullish | 6/10 | HUTCHMED announced that two positive Phase III studies of savolitinib plus osimertinib in NSCLC were selected for oral p | Sep 24, 2026 |
| LODE | PRESS-RELEASE | neutral | 4/10 | Comstock Inc. announced that its portfolio company Sierra Springs Opportunity Fund (SSOF) has engaged Newmark to advise | Sep 24, 2026 |
| IMRN | 6-K | neutral | 2/10 | Immuron Ltd filed its Appendix 4G and Corporate Governance Statement for the fiscal year ended 30 June 2026 with the ASX | Sep 24, 2026 |
| JAGX | 8-K | bearish | 6/10 | Jaguar Health issued 547,898 common shares to Streeterville Capital in exchange for a $5,049,909.26 reduction in the out | Sep 24, 2026 |
| KYTX | 8-K | bullish | 7/10 | Kyverna Therapeutics reported positive one-year durability data from its registrational KYSA-8 trial of miv-cel in stiff | Sep 24, 2026 |